International Journal of Scientific Research and Modern Technology (IJSRMT) ijsrmt.com
Volume 2, Issue 12, 2023
DOI: https://doi.org/10.38124/ijsrmt.v2i12.1037

AI-Integrated Market Access Strategies in Oncology: Using Predictive Analytics to Navigate Pricing, Reimbursement and Competitive Landscapes

Ezichi Adanna Anokwuru[1]; Mends Karen, Y. O.[2]; Onum Friday Okoh[3]

[1]Fisher College of Business, The Ohio State University, Columbus OH, USA.
[2]School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
[3]Department of economics, university of Ibadan, Ibadan, Nigeria.

Publication Date: 2023/12/29

Abstract

The integration of Artificial Intelligence (AI) into oncology market access strategies is revolutionizing how pharmaceutical companies navigate complex pricing, reimbursement, and competitive landscapes. AI-driven predictive analytics enables more precise forecasting of payer decisions, pricing trends, and competitive behaviors, improving strategic alignment across stakeholders. Findings from recent industry applications reveal that AI models enhance pricing accuracy by identifying optimal reimbursement thresholds and forecasting patient access outcomes more efficiently than traditional methods. Additionally, predictive analytics has proven effective in identifying high-value market segments, optimizing resource allocation, and reducing delays in therapy adoption. The findings suggest that AI integration not only supports data-driven decision-making but also fosters transparency and adaptability in value-based oncology care. The study concludes that leveraging AI tools in oncology market access improves efficiency, accuracy, and equity in healthcare delivery while enabling proactive responses to market volatility. It emphasizes that the future of oncology access will depend on how effectively stakeholders integrate predictive systems with clinical and real-world data to support sustainable innovation. Based on the findings, it is recommended that pharmaceutical firms, regulators, and payers invest in interoperable AI infrastructures, data governance frameworks, and cross-sector collaboration to ensure that predictive insights translate into accessible, affordable, and impactful cancer therapies.

Keywords: *Artificial Intelligence, Predictive Analytics, Oncology, Market Access, Pricing and Reimbursement.*

I. INTRODUCTION

➢ *Background on Market Access Challenges in Oncology*

The oncology therapeutic area presents unique market access challenges, primarily driven by high research and development costs, rapid innovation, and complex evidence requirements. Barrios et al. (2022) note that novel anticancer therapies often face delayed or restricted reimbursement due to high pricing and uncertain clinical benefit, compounded by resource-constrained health systems. These structural barriers create inequities in patient access, where regulatory approval does not necessarily translate into timely availability. Examples include innovative targeted therapies and immuno-oncology drugs, which may remain inaccessible in low- and middle-income countries due to prohibitive costs and limited healthcare infrastructure. This landscape emphasizes the critical need for strategic approaches to pricing, reimbursement negotiations, and value demonstration to ensure effective access (Amebleh & Omachi, 2022).

In addition, therapies with immature clinical evidence frequently confront reimbursement obstacles. Simoens, De Groote, and Boersma (2022) highlight those oncology treatments, particularly those supported by single-arm trials or surrogate endpoints, challenge traditional health technology assessment frameworks.

Payers often require additional real-world evidence or performance-based agreements to justify coverage, which can slow patient access. Consequently, oncology market access is characterized by the interplay of high costs, uncertain value, and constrained payer systems, forming a complex backdrop against which pharmaceutical companies must craft predictive, data-informed strategies to optimize both reimbursement and patient access (Amebleh et al., 2021).

- *The Emergence of Artificial Intelligence in Healthcare Decision-Making*

The increasing deployment of artificial intelligence (AI) within healthcare decision-making reflects a paradigm shift where digital models supplement and in some cases out-pace traditional clinician judgment. Osamah et al. (2022) report that AI-driven systems are being leveraged to analyse large-scale clinical datasets, flag anomalies (e.g., radiographic patterns), and generate diagnostic suggestions more rapidly than conventional workflows. For example, convolutional neural networks applied to imaging tasks can identify nodules with accuracy surpassing that of many human specialists, thereby influencing therapeutic decisions earlier. Within oncology this means that pre-treatment stratification, real-world evidence synthesis and throughput of patient eligibility decisions can be markedly expedited by AI modules embedded in market-access and pricing strategy pipelines (Atalor, 2019).

However, integration of AI into decision-making is not simply a technological upgrade; it challenges the traditional human-centric model of shared decision-making. Rahimi et al. (2022) found that while AI shows promise in supporting collaborative decisions between providers and patients, the literature remains nascent in exploring how algorithms account for patient preferences, values or ethical trade-offs in treatment choice. In oncology market-access context, where reimbursement, value-based pricing, and competitive positioning are interwoven, the emergence of AI implies that predictive models may alter stakeholder negotiations, value-proposition frameworks and health-system access pathways (Atalor, 2022).

- *Rationale and Objectives of AI-Integrated Market Access*

The rationale for integrating Artificial Intelligence (AI) into oncology market access lies in the increasing complexity of healthcare systems, the proliferation of high-cost therapies, and the pressing demand for data-driven precision in pricing and reimbursement decisions. Traditional market access frameworks often rely on static models that cannot accommodate the dynamic interplay of clinical evidence, payer expectations, and patient outcomes. AI offers an unprecedented capability to synthesize vast volumes of heterogeneous data clinical trials, real-world evidence, epidemiological trends, and market signals into actionable intelligence. By doing so, it enhances forecasting accuracy, identifies optimal reimbursement pathways, and supports adaptive pricing strategies that align with evolving regulatory and payer environments. The integration of AI ensures that market access strategies become predictive rather than reactive, improving transparency and efficiency across the entire oncology value chain.

The key objective of AI-integrated market access is to optimize decision-making processes that balance affordability, innovation, and patient access. It seeks to create a learning ecosystem where predictive analytics continuously inform stakeholder strategies, from clinical development to post-launch evaluation. This framework enables pharmaceutical firms to anticipate payer behavior, simulate competitive responses, and tailor value communication to specific healthcare contexts. Furthermore, it promotes equity by identifying patient populations most likely to benefit from timely access to innovative therapies. Ultimately, AI-driven market access aims to harmonize commercial sustainability with societal health priorities, ensuring that oncology innovations reach patients efficiently while maintaining economic viability for healthcare systems.

- *Structure of the Paper*

This paper is organized into seven main sections to provide a comprehensive analysis of AI-integrated market access strategies in oncology. The introduction presents the background, rationale, and objectives of the study, establishing the relevance of AI in healthcare decision-making. The second section explores predictive analytics and machine learning applications, highlighting data-driven insights for pricing, reimbursement, and value-based healthcare models. The third section focuses on pricing strategies, including forecasting trends, dynamic optimization, and case-based insights in oncology markets. The fourth section examines reimbursement strategies, addressing predictive modeling for payer behavior, health technology assessment, and evidence generation. Section five analyzes market intelligence, emphasizing AI tools for forecasting, launch sequencing, and identifying unmet needs. The sixth section synthesizes key findings, conclusions, and global implications, connecting the study's insights to broader oncology market access strategies. Finally, the seventh section discusses strategic recommendations, including strengthening AI infrastructure, promoting cross-sector collaboration, and outlining future directions for AI-driven market access, ensuring a coherent framework that aligns technical, strategic, and practical considerations throughout the paper.

II. CONCEPTUAL FRAMEWORK OF AI IN ONCOLOGY MARKET ACCESS

- *Overview of Predictive Analytics and Machine Learning Applications*

Predictive analytics represents a cornerstone of modern healthcare decision-making, leveraging large-scale data integration to identify trends, forecast outcomes, and optimize treatment and policy decisions. In oncology, machine learning (ML) applications have evolved from simple regression-based models to sophisticated multimodal systems capable of merging genomic, imaging, and clinical data for comprehensive disease insight (Kline et al., 2022). These models not only enhance early cancer detection and treatment personalization but also support payer and policy decisions by quantifying potential clinical and economic outcomes. For instance, predictive models can simulate therapy responses across diverse patient populations, assisting market access teams in demonstrating real-world value and cost-effectiveness for reimbursement negotiations (Atalor, 2022).

Despite these advancements, the utility of predictive analytics in oncology still depends on data quality, contextual adaptation, and algorithmic transparency. Adeoye et al. (2022) emphasized that while ML-based cancer outcome models improve precision in resource-limited settings, they often face challenges related to data incompleteness and insufficient validation. These limitations underscore the importance of integrating robust data governance and model explainability within predictive analytics frameworks. In the context of oncology market access, machine learning applications serve as essential tools for forecasting payer behavior, optimizing pricing strategies, and supporting equitable patient access, ultimately bridging clinical innovation with economic sustainability (Grace &Okoh, 2022).

➢ *Data-Driven Insights in Pricing and Reimbursement*

In the realm of oncology market access, the use of data-driven insights has become indispensable for shaping pricing and reimbursement strategies. For multi-indication therapeutics, Ha et al. (2022) as represented in table 1 demonstrate that indication-specific value-based pricing models can vary dramatically between 28.6 % and 328.8 % of current list prices based on cost-effectiveness and budget impact. This indicates the necessity for granular data: real-world utilization, indication volume, incremental cost-effectiveness, and reimbursement thresholds all feed into predictive pricing models. By integrating these disparate data streams, manufacturers and payers can simulate pricing scenarios and budget impact outcomes, allowing more informed decision-making around reimbursement negotiation, launch sequencing, and risk-sharing agreements.

Furthermore, Poveda et al. (2022) show that the adoption of artificial intelligence (AI) and real-world data analytics in value-based contracting enables dynamic alignment of payment to performance. The authors describe how natural language processing of electronic health records and large-scale data analytics permits monitoring of outcome-linked reimbursement triggers, enabling payers to mitigate risk and manufacturers to align pricing with real-world benefit. In oncology, where therapies are high-cost and benefit profiles may evolve post-launch, these data-driven insights support adaptive pricing models and reimbursement pathways that reflect actual patient and payer behaviour rather than static assumptions (Atalor, 2022).

Table 1 Summary of Data-Driven Insights in Pricing and Reimbursement

Insight Area	Description	AI/Analytics Application	Example in Oncology
Pricing Forecasting	Predicting optimal drug pricing based on market, competitor, and payer data	Machine learning models analyze historical pricing trends, payer responses, and patient demand	AI predicts optimal launch price for a new immunotherapy considering payer willingness-to-pay and competitor pricing
Reimbursement Probability	Estimating likelihood of coverage and reimbursement from payers	Predictive analytics evaluates payer policies, HTA outcomes, and regional regulations	AI models estimate the probability of national reimbursement for a targeted therapy in multiple countries
Value Proposition Assessment	Quantifying clinical and economic benefits to support pricing and reimbursement	Data-driven simulations integrate real-world evidence, cost-effectiveness, and patient outcomes	Using real-world survival and cost data to demonstrate the value of CAR-T therapy to payers
Competitive Benchmarking	Assessing competitor strategies and market positioning	AI monitors competitor launches, pricing adjustments, and promotional activities	Predictive tools forecast how competitor oncology therapies could impact uptake and reimbursement approval timelines

➢ *Linking AI Technologies to Value-Based Healthcare Models*

The integration of AI into value-based healthcare (VBHC) models represents a critical evolution in aligning innovation with outcomes rather than volume. AI technologies enable real-time monitoring of patient outcomes, stratification of benefit populations, and dynamic recalibration of reimbursement models. For example, Parikh et al. (2022) as presented in figure 1 outline how payment frameworks for AI applications in medicine are shifting from procedural or volume-based reimbursement toward outcome-based structures that reward performance, interoperability, and bias mitigation. In oncology market access, this translates into value propositions where AI-derived evidence such as predictive response rates or sub-population risk modeling directly feeds into reimbursement discussions and pricing tiers tied to patient benefit profiles.

Moreover, the capacity of AI to extract insights from large real-world datasets supports the structuring of value-based contracts and managed entry agreements. Poveda et al. (2022) illustrate how natural language processing and advanced analytics permit the measurement of treatment effectiveness in actual practice, enabling outcomes-linked pricing and risk-sharing agreements between manufacturers and payers. Within oncology, linking AI-enabled patient segmentation, predictive modelling of outcomes and performance-based reimbursement fosters a loop where pricing and access strategies are adaptively refined and aligned with actual value delivered (Gracea &Okohb, 2022).

Figure 1 outlines a layered AI ecosystem that links real-time physiological data to value-based healthcare by transforming raw sensor inputs into actionable, cost-effective outcomes. At the Sensing Layer, wearable capture ECG, SpO2, glucose, and motion data; the Connectivity Layer aggregates this via secure gateways to the Cloud/Processing Layer, where preprocessing, missing-data imputation, and standardization feed trained AI models for predictive analytics. The User Application Layer then delivers personalized insights alerting patients, guiding doctors, and optimizing hospital resource use shifting care from reactive volume to proactive value: reducing readmissions, enabling early interventions, and aligning reimbursements with health outcomes, all while ensuring data interoperability and privacy under value-based models like ACOs and bundled payments.



Fig 1 Picture of AI-Powered Value-Based Care: From Sensors to Outcomes Parikh et al. (2022)

III. AI AND PREDICTIVE ANALYTICS IN PRICING STRATEGY DEVELOPMENT

- *Forecasting Pricing Trends through Machine Learning Models*

Forecasting pricing trends through machine learning (ML) models provides a data-driven framework for evaluating and predicting fluctuations in drug pricing, particularly within oncology markets. By analyzing large-scale datasets encompassing clinical outcomes, patient demographics, and payer policies, ML algorithms can recognize latent patterns that influence price evolution. According to Ha et al. (2022), the integration of budget impact analysis with value-based pricing enables policymakers and pharmaceutical firms to evaluate cost-effectiveness across multiple indications. ML systems can automate this process by quantifying relationships between drug efficacy, population reach, and incremental cost-effectiveness ratios, thereby supporting dynamic price optimization and market entry strategies (Idika et al., 2021).

Furthermore, the adaptability of ML in forecasting pricing trends lies in its predictive precision under uncertain market conditions. Poveda et al. (2022) emphasize that artificial intelligence can streamline value-based contracting by forecasting payer responses and optimizing reimbursement negotiations. Predictive models, such as neural networks or gradient boosting algorithms, can simulate future pricing outcomes based on policy shifts, competitor entries, and therapeutic innovations. These insights allow stakeholders to refine pricing frameworks, balance affordability with profitability, and ensure sustainable access to high-cost oncology treatments in a rapidly evolving healthcare economy (Ihimoyan et al., 2022).

- *Dynamic Pricing Optimization and Competitive Positioning*

Dynamic pricing optimization and competitive positioning involve leveraging artificial intelligence (AI) and machine learning (ML) models to predict market fluctuations and adjust pricing strategies in real time. According to Chandra and Shukla (2022), AI-driven dynamic pricing relies on reinforcement learning algorithms that continuously analyze consumer behavior, competitor prices, and demand elasticity to maximize revenue without compromising market share. These systems adaptively learn from historical transactions and competitive feedback, thereby allowing healthcare and pharmaceutical firms to dynamically adjust drug prices in response to changes in patient affordability, insurance reimbursement, and competitor launches. Such intelligence-driven frameworks strengthen competitive positioning by aligning price variability with both market demand and long-term value creation (Ijiga et al., 2021).

Moreover, ML-based optimization tools enhance precision in price benchmarking and forecasting, improving firms' responsiveness to competitive pressures. Ramanathan et al. (2022) highlight that these tools integrate external variables such as regional purchasing power, government regulations, and health technology assessments to support strategic pricing decisions. For instance, pharmaceutical firms can employ predictive analytics to identify price inflection points that optimize both profit margins and patient access. This dynamic integration of AI in pricing and competition modeling ensures evidence-based positioning that balances innovation incentives with sustainable affordability in global healthcare markets.

- *Case Insights on AI-Supported Oncology Pricing Decisions*

AI-supported oncology pricing decisions have emerged as a transformative approach to optimizing the balance between therapeutic value and affordability. Bates et al. (2022) as represented in figure 2 and table 2 emphasize that oncology drug pricing involves complex assessments of clinical efficacy, biomarker-driven response rates, and long-term survival outcomes, which AI systems can analyze more effectively than traditional models. Predictive algorithms integrate real-world evidence and patient-level data to simulate treatment outcomes, thereby informing pharmaceutical firms about the most cost-effective pricing strategies. For example, AI-enabled pricing platforms in oncology have been used to model drug value trajectories based on patient-reported outcomes and adverse event data, guiding reimbursement negotiations with payers. These tools reduce uncertainty by aligning pricing with evidence of clinical benefit, ultimately improving patient access and payer confidence (Ijiga et al., 2021).

Furthermore, AI-driven case applications demonstrate how pharmaceutical firms can employ dynamic market analytics to forecast price elasticity and adapt strategies across diverse oncology portfolios. Mullin et al. (2022) note that AI-enabled simulations in cancer therapeutics, such as immuno-oncology agents, help determine value-based reimbursement thresholds through continuous monitoring of comparative effectiveness data. Such insights allow firms to adjust launch prices, optimize payer alignment, and justify reimbursement tiers in response to evolving treatment evidence. These cases underscore AI's strategic role in harmonizing pricing efficiency with clinical and economic outcomes within the oncology market landscape.



Fig 2 Picture of AI-Driven Framework Supporting Oncology Pricing Decisions (Bates et al. 2022).

Figure 2 illustrates how AI-driven systems support oncology decision-making, which can also be applied to pricing strategies for cancer treatments. By integrating oral oncology data with AI-powered clinical decision support systems (AI-CDSS), healthcare providers can achieve earlier and more accurate detection, diagnosis, and treatment planning. In the context of oncology pricing, these same AI tools can analyze clinical outcomes, patient characteristics, treatment effectiveness, and resource utilization to determine fair, evidence-based prices for cancer therapies. Ethical considerations ensure transparency and equity in pricing, while clinical impact assessments help align costs with actual patient benefits. Overall, AI enhances the precision, fairness, and sustainability of oncology pricing decisions by combining clinical insight with data-driven analysis.

Table 2 Summary of Case Insights on AI-Supported Oncology Pricing Decisions

Case Insight	Description	AI/Analytics Application	Example in Oncology
Price Optimization	Using AI to determine the most effective pricing strategy for new oncology drugs	Machine learning models simulate multiple pricing scenarios considering payer policies, patient demand, and competitor pricing	AI recommends a launch price for a novel targeted therapy based on predicted payer approval likelihood and market uptake
Competitive Intelligence	Assessing competitor behavior and market dynamics	Predictive analytics evaluates competitor launch timing, pricing adjustments, and market share	AI forecasts the impact of a rival immunotherapy entering the market on reimbursement and adoption of an existing therapy
Risk Mitigation	Reducing uncertainty in pricing and reimbursement outcomes	Scenario modeling and sensitivity analysis quantify potential financial and market risks	AI identifies risk of payer rejection for a high-cost CAR-T therapy and suggests alternative value-based pricing models
Launch Sequencing	Prioritizing markets or indications for product rollout	Predictive models rank markets based on payer receptivity, patient need, and revenue potential	AI determines optimal sequence for launching an oncology drug across multiple countries to maximize access and profitability

IV. REIMBURSEMENT PATHWAYS AND VALUE ASSESSMENT

➢ *Predictive Modeling for Payer Behavior and Reimbursement Outcomes*

Predictive modeling for payer behavior and reimbursement outcomes is increasingly vital in oncology market-access planning, where reimbursement decisions hinge on multi-dimensional value signals and budget-impact projections. An integrated valuation model as proposed by Nuijten (2022) as represented in table 3 demonstrates how combining payer willingness-to-pay thresholds, discounted cash-flow methods, and investor return expectations creates a framework through which pharmaceutical companies can anticipate payer decisions and negotiate more effectively. By integrating real-world evidence, longitudinal survival data, and that model's outputs, manufacturers can structure pricing and reimbursement submissions to align with payer thresholds in different markets.

Within oncology, the interaction between value frameworks and payer decisions is further elaborated by Binder (2022), who reviewed how health-technology-assessment (HTA) processes in Canada adjust reimbursement recommendations based on cost-per QALY thresholds that have been reduced over time. Binder's findings indicate that predictive models must incorporate evolving payer standards, willingness-to-pay drops, and indication-specific thresholds for oncology drugs. In this context, predictive analytics systems that are calibrated with historical reimbursement outcomes, budget-impact models and payer policy shifts can help forecast acceptance probabilities, negotiate managed entry agreements and optimize product launch sequencing in global markets (Ijiga et al., 2021).

Table 3 Summary of Predictive Modeling for Payer Behavior and Reimbursement Outcomes

Predictive Modeling Focus	Description	AI/Analytics Application	Example in Oncology
Payer Decision Simulation	Modeling payer coverage and reimbursement decisions	Machine learning algorithms predict payer acceptance based on historical coverage patterns, HTA outcomes, and policy changes	AI predicts likelihood of a new immunotherapy being reimbursed in multiple regions based on prior approvals for similar drugs
Reimbursement Timeline Forecasting	Estimating time to approval and payment for new therapies	Predictive analytics simulates HTA review processes, pricing negotiations, and policy delays	AI estimates that a novel CAR-T therapy will achieve reimbursement within 9 months in major European markets
Coverage Criteria Assessment	Understanding payer-specific requirements for approval	Natural language processing and data mining analyze payer guidelines and past decision letters	AI identifies key clinical endpoints payers require for reimbursing a targeted oncology therapy
Risk and Impact Analysis	Evaluating potential financial and market implications of payer decisions	Scenario modeling quantifies revenue variability under different coverage outcomes	AI models assess revenue risk if a high-cost oncology drug is initially denied reimbursement in key markets

- *AI in Health Technology Assessment (HTA) and Value Communication*

In the context of health technology assessment (HTA), artificial intelligence (AI) is being increasingly positioned as a critical enabler of value communication between manufacturers, payers, and other stakeholders. The reimbursement framework proposed by Abràmoff et al. (2022) as presented in figure 3 emphasizes how AI services must be monetized based on performance, transparency, and measurable outcomes shifting the communication of value from static dossiers to dynamic data-driven narratives. For oncology market access, this means that manufacturers can deploy AI-derived analytics (for example, predictive biomarker response models or longitudinal real-world outcome simulations) to articulate differentiated value propositions for each indication, and communicate these in HTA submissions and payer negotiations with greater granularity and credibility.

Yet the adoption of AI within HTA and value communication is constrained by structural and methodological barriers. Tachkov et al. (2022) document that among Central and Eastern European HTA systems, key obstacles include heterogeneous data sources, lack of methodological transparency, and limited regulatory familiarity with AI-driven evidence frameworks. These issues undermine the ability of AI-enabled value communication to influence HTA decisions reliably. To address this, value communication strategies must incorporate explainability, robust model validation, and clear linkage of AI-generated evidence to meaningful clinical and economic endpoints thereby ensuring that HTA bodies interpret and trust the AI-supported value narrative in oncology market-access contexts (Ijiga et al., 2022).

Figure 3 depicts AI as the central engine in Health Technology Assessment (HTA) and value communication, integrating four key domains: patient data and diagnostics feed real-world evidence into predictive medicine models; clinical decision-making leverages AI-driven analytics for personalized treatment pathways; health services management optimizes resource allocation and cost-effectiveness; and all converge to generate transparent, evidence-based value narratives. This ecosystem enables HTA bodies to assess clinical and economic outcomes faster, supports payers with dynamic value dossiers, and empowers providers and patients with clear, AI-validated benefit-risk profiles accelerating reimbursement, adoption, and equitable access to innovative therapies.



Fig 3 Diagram of AI-Powered HTA: Value in Healthcare (Abràmoff et al., 2022).

- *Enhancing Evidence Generation for Reimbursement Approvals*

Within the landscape of oncology market access, evidence generation for reimbursement approvals has evolved to embrace AI-driven methodologies that can convert vast and heterogeneous real-world data (RWD) into decision-grade real-world evidence (RWE). Preston et al. (2022) illustrate how deep-learning based natural language processing (NLP) models can extract tumour attributes, treatment histories and outcomes from free-text clinical documents with AUROCs of 94-99 % across large-scale datasets. Such structured data augmentation enables manufacturers and payers to build longitudinal outcome models, stratify patient cohorts by biomarker and response, and thereby underpin submissions with higher-fidelity evidence of effectiveness, safety, and value (Ijiga et al., 2021).

Furthermore, Regier et al. (2022) argue that a life-cycle health technology assessment (HTA) framework is increasingly required for precision oncology, whereby continuous evidence generation post-launch is essential to meet reimbursement demands. AI plays a central role by enabling real-time monitoring of outcomes, adaptive modelling of cost-effectiveness, and dynamic update of value dossiers as treatment patterns evolve. In oncology therapies especially, where long follow-up and small patient sub-groups complicate traditional evidence generation, these AI-enabled workflows create credible pipelines for reimbursement approvals by aligning evidence production with payer expectations, reducing uncertainty and supporting managed access agreements.

V. COMPETITIVE LANDSCAPE ANALYSIS IN ONCOLOGY MARKETS

- *AI Tools for Market Forecasting and Competitor Intelligence*

AI tools have become essential for market forecasting and competitor intelligence, enabling oncology firms to synthesize vast amounts of structured and unstructured data to anticipate market trends. Haleem et al (2022) as presented in figure 4 demonstrate that AI algorithms can process competitor product launches, payer policy changes, and patient sentiment to deliver detailed forecasts beyond conventional analytics. These insights allow firms to estimate competitive entry timelines, project market share fluctuations, and anticipate pricing adjustments, supporting proactive market-access strategies that align product launch planning with real-world market dynamics.

Moreover, AI enhances strategic positioning by enabling continuous monitoring of competitor activity and market signals. Mishra and Krishnaswamy (2022) show that AI-focused firms outperform in operational efficiency and competitive adaptability. In oncology, predictive models can detect early signs of competitor pipeline movements or shifts in reimbursement policies. Integrating these insights into dynamic dashboards allows firms to adjust launch sequencing, tailor pricing strategies, and refine value propositions in near real-time, ensuring agility in highly competitive oncology markets and optimizing access, revenue, and market penetration.

Fig 4 Picture of AI: Forecasting Markets, Outsmarting Rivals (Haleem et al., 2022).

Figure 4 captures AI and machine learning as transformative tools in market forecasting and competitor intelligence, where a humanoid robot and human analyst collaborate on a dynamic holographic dashboard. AI algorithms process vast datasets sales trends, social sentiment, and competitor pricing in real time, delivering predictive models with 80-90% accuracy, while natural language processing extracts strategic insights from earnings calls and patents. This fusion enables proactive market positioning, rapid response to competitive threats, and data-driven decision-making, turning raw information into actionable foresight for sustained market advantage.

- *Predictive Simulation for Launch Sequencing and Lifecycle Management*

Predictive simulation tools have become pivotal for orchestrating launch sequencing and lifecycle management in oncology markets. Rajora (2022) as represented in table 4 illustrates the importance of enterprise system readiness for launch operations, emphasizing that data-driven inputs such as regulatory timelines, supply-chain capacity, and early patient uptake must feed into simulation engines to optimize regional launch order and resource allocation. In the oncology context, simulation models can integrate real-world uptake curves, indication expansion schedules and competitor entry timelines to forecast the optimal sequence in which geographic markets should be addressed. This enables manufacturers to prioritise high-value regions, align pricing and reimbursement strategies, and synchronise launch activities with payer readiness and HTA submissions.

Meanwhile, Ogayemi (2022) presents a market-access optimisation model where AI-driven forecasting simulates not only launch timing but also lifecycle events such as line extensions, indication expansions and patent cliffs. By integrating machine-learning-based scenario analysis with reimbursement outcome probabilities and competitor reaction modelling, oncology firms can develop adaptive launch-and-lifecycle plans. For instance, the simulation might predict the time-to-market for a second indication, estimate revenue attrition upon generic entry, and recommend either accelerated launch sequencing or delayed rollout depending on the modeled value erosion. Such predictive simulation thus anchors lifecycle management decisions in actionable insights rather than static forecast tables (Ijiga et al., 2022).

Table 4 Summary of Predictive Simulation for Launch Sequencing and Lifecycle Management

Simulation Focus	Description	AI/Analytics Application	Example in Oncology
Launch Sequencing	Prioritizing markets, indications, or patient populations for drug rollout	Predictive models evaluate payer receptivity, competitive landscape, and market potential	AI recommends launching a targeted therapy first in countries with higher reimbursement probability and unmet patient need
Market Uptake Forecasting	Estimating patient adoption rates and prescription volumes	Machine learning algorithms analyze historical uptake patterns, patient demographics, and treatment guidelines	AI predicts early adoption rates for a CAR-T therapy across multiple regions to optimize supply chain planning
Lifecycle Optimization	Planning for product extensions, new indications, and reformulations	Scenario analysis simulates revenue, market share, and access outcomes over time	AI identifies the optimal timing for expanding a therapy's indication to maximize long-term revenue and market penetration
Risk Mitigation	Anticipating regulatory, market, or payer barriers	Predictive simulations quantify potential delays and market access risks	AI flags potential reimbursement delays in specific countries and suggests alternative launch sequencing to mitigate revenue loss

➢ *Identifying Market Opportunities and Unmet Needs Using AI*

In the rapidly evolving oncology market, AI tools have emerged as critical enablers for identifying market opportunities and unmet clinical needs by analysing large-scale imaging, genomics and real-world outcome datasets to surface therapeutic gaps and underserved indications. For example, Koh et al. (2022) point out that AI and machine learning applied to cancer imaging workflows can detect nuanced tumour phenotypes, longitudinal response patterns and imaging biomarkers that were previously latent in conventional analyses thus illuminating new patient segments and unmet needs where novel therapies might generate differentiated value. In oncology market access, leveraging these AI-driven insights allows manufacturers to pinpoint indications with high residual need (e.g., biomarker-negative relapsed populations, rare tumour subtypes with high unmet mortality) and tailor product value propositions accordingly.

Moreover, the role of AI in strategic market-identification extends into the domain of medical affairs and unmet-need mapping. Fröling et al. (2022) describe how AI-enabled analytics within medical affairs departments facilitate the 58rioritization of care gaps by quantifying disease burden, treatment-churn, off-label usage and patient-reported outcomes across geographies enabling firms to align development or launch decisions with maximal access and commercial potential. In oncology, this means combining epidemiologic modelling, competitive landscape scanning and reimbursement-environment data (via AI) to identify regions or indications where payer thresholds are less saturated, and where unmet need remains acute (e.g., orphan oncology indications, markets with weak pipeline competition) (Ilesanmi, et al., 2023). By systematically integrating these AI-derived opportunity signals, companies can sharpen their market-entry strategy, tailor lifecycle planning and deliver therapies into high-value niches that simultaneously serve patient needs and reimbursement viability (James, 2022).

VI. SYNTHESIS OF AI-ENABLED ADVANCES IN ONCOLOGY MARKET ACCESS

➢ *Key Findings from AI Integration in Market Access*

The integration of artificial intelligence (AI) into market-access strategies has yielded several critical findings that align with the evolving oncology landscape. Mullin et al. (2022) as represented in table 5 found that AI-enabled analytics significantly improve the precision of value-based pricing models in oncology by allowing manufacturers to stratify patient populations, assess indication-specific benefit, and run scenario simulations of payer uptake and reimbursement outcomes. This capability helps align high launch prices with realistic market access trajectories, reducing mispricing risk and support's payers' willingness to reimburse. Similarly, Parikh, Knoll, and Dedhia (2022) highlighted that the adoption of AI allows health-systems and manufacturers to shift from static fee-for-service pricing to outcome-linked reimbursement frameworks that adapt as real-world evidence accumulates (Okoh & Grace, 2022).

Furthermore, these studies reveal that AI's major impact lies not just in pricing but in the entire access ecosystem from early evidence generation through competitive and payer modelling. AI-driven tools have demonstrated the ability to model payer behaviour, predict HTA outcomes and optimise the sequencing of launches to maximise access and reimbursement success (Ocharo, et al., 2023). Collectively, these key findings underscore that AI is not merely a tactical tool but a strategic enabler of sustainable access and value realisation in oncology markets.

Table 5 Summary of Key Findings from AI Integration in Market Access

Key Finding	Description	AI/Analytics Application	Example in Oncology
Enhanced Pricing Accuracy	AI improves the precision of pricing strategies by integrating market, payer, and clinical data	Machine learning predicts optimal launch prices, pricing tiers, and reimbursement likelihood	AI identifies the most effective price for a new immunotherapy across multiple countries based on payer behavior and competitor pricing
Improved Reimbursement Forecasting	Predictive analytics estimates payer decisions and timelines more reliably	Algorithms simulate coverage probability and reimbursement delays	AI forecasts the likelihood and timing of HTA approval for a novel targeted therapy
Market Opportunity Identification	AI detects unmet needs and high-value patient segments	Data-driven models analyze real-world outcomes, epidemiology, and competitive dynamics	AI identifies patient populations most likely to benefit from CAR-T therapies for focused access strategies
Strategic Launch Sequencing	Optimizing rollout across regions and indications	Scenario modeling ranks markets based on payer receptivity, market size, and competitive landscape	AI recommends launching a therapy first in regions with favorable reimbursement and high unmet demand

➢ *The Role of Predictive Analytics in Oncology Access*

The deployment of predictive analytics within oncology market access has fundamentally shifted how manufacturers and payers anticipate value, access, and reimbursement dynamics. Mullin et al. (2022) as presented in figure 5 demonstrate that AI-enabled segmentation of responsive patient populations and indication-specific modelling of reimbursement scenarios markedly reduce uncertainty in pricing and access strategies. By leveraging predictive insights into uptake curves, payer behavior, and competitive response, these analytics allow firms to align launch pricing and access sequencing more closely with real-world market realities (Anokwuru, et al., 2022). This fosters a move from reactive launch tactics to proactive access management.

Simultaneously, Parikh, et al., (2022) indicate that predictive analytics support the transition from volume-based to performance-based reimbursement frameworks by providing timely evidence on therapeutic outcomes and value realization. In oncology, where long-term outcomes and heterogeneous patient responses pose significant access barriers, such analytics provide the infrastructure for dynamic contracting and real-world-evidence-driven price adjustments (Oyekan, et al., 2023). Collectively, these findings affirm that predictive analytics has become a strategic pillar enabling oncology market access strategies that are not only data-informed but also value-aligned, equitable, and sustainable in highly competitive and regulated environments.

Figure 5 illustrates predictive analytics as a central driver in oncology access, enabling early diagnosis through biomarker pattern recognition, accurate prognosis via survival modeling, and personalized treatment courses using genomic and real-world data. It supports clinical decision-making with risk-stratified protocols, reduces adverse events through preemptive toxicity alerts, and facilitates remote monitoring for rural patients collectively lowering healthcare costs, improving care quality, and accelerating equitable access to life-saving cancer therapies.



Fig 5 Diagram of Analytics for Oncology Access Mullin et al. (2022).

➢ *Implications for Global Oncology Pricing and Access Strategies*

The integration of predictive analytics and AI into oncology pricing and access strategies carries profound global implications, especially as therapeutic innovation accelerates and healthcare systems diverge in budgetary capacity and regulatory frameworks. Parikh and Helmchen (2022) highlight that AI-driven reimbursement models are shifting from volume-based to outcome-based structures, creating an imperative for manufacturers to tailor pricing across geographies by leveraging real-world evidence that reflects local payer behaviour and value thresholds. In global oncology markets, this means companies must deploy scenario modelling that incorporates regional pricing tiers, managed-entry agreements, and indication-specific rollout strategies grounded in predictive analytics.

Moreover, the life-cycle HTA perspective advanced by Regier et al. (2022) underscores that access strategies must evolve beyond initial launch pricing to consider post-launch evidence, indication expansion, and real-world performance data. For global oncology assets, this translates into dynamic access planning where AI-enabled analytics track competitive entry timing, patient uptake and payer responses across markets. Consequently, access strategies must not be monolithic but inherently adaptive differentiated by market maturity, payer sophistication, and infrastructure readiness and anchored in predictive insights that balance innovation, equity and sustainable pricing (Ijiga et al., 2021).

VII. CONCLUSION AND RECOMMENDATIONS

- *Conclusion on Strengthening AI Infrastructure and Data Governance*

Strengthening AI infrastructure and data governance is central to achieving sustainable, transparent, and scalable advancements in market-access systems. Robust infrastructure ensures that AI tools operate with high efficiency, reliability, and interoperability across diverse health-care environments. When supported by secure data architecture, real-time analytics, and strong computational capacity, AI becomes a powerful mechanism for improving pricing precision, shaping reimbursement pathways, and enhancing evidence generation throughout the product-lifecycle. This creates a more responsive, predictable, and balanced market-access environment for all stakeholders, including manufacturers, payers, and patients.

Equally important is the establishment of strong data-governance frameworks that guarantee accuracy, privacy, and ethical use of sensitive health information. Clear governance structures promote confidence in AI-generated insights by reducing data biases, enabling appropriate access controls, and ensuring consistency in data-handling practices. By embedding these principles into the broader health-care system, organisations can unlock the full strategic potential of AI while safeguarding trust and transparency. Ultimately, a well-developed AI infrastructure coupled with sound data governance forms the foundation for long-term innovation and equitable access across oncology markets.

- *Encouraging Cross-Sector Collaboration and Transparency*

Cross-sector collaboration is essential for leveraging AI effectively in oncology market access, as it enables the sharing of expertise, data, and resources across pharmaceutical companies, healthcare providers, payers, and regulatory agencies. Collaborative initiatives can accelerate the development and validation of AI models by integrating diverse datasets, including clinical trial results, real-world patient outcomes, and market intelligence. By pooling knowledge from multiple stakeholders, organizations can generate more robust predictive analytics, improve market forecasting, and identify unmet medical needs with higher accuracy. Collaboration also fosters innovation, as joint efforts in algorithm development and scenario testing help refine strategies for pricing, reimbursement, and competitive positioning, ultimately enhancing patient access to new therapies.

Transparency plays a complementary role by building trust among stakeholders and ensuring that AI-driven insights are understandable, reliable, and actionable. Clear communication of model assumptions, data sources, and limitations allows payers, providers, and regulators to assess the validity of predictions and make informed decisions. Transparent reporting also supports ethical AI practices by highlighting potential biases, methodological choices, and the rationale behind strategic recommendations. Together, cross-sector collaboration and transparency create an environment in which AI can drive data-informed decision-making, foster stakeholder confidence, and strengthen the adoption of innovative market access strategies in oncology.

- *Recommendations for AI-Driven Market Access in Oncology*

Advancing AI-driven market access in oncology requires strategic investment in tools, processes, and collaborations that enhance decision-making across the product-lifecycle. Stakeholders should prioritize building integrated platforms that combine clinical, economic, and real-world data to support more accurate pricing, reimbursement forecasting, and patient-outcome modelling. Manufacturers and payers can further strengthen decision quality by adopting transparent AI workflows that clearly document how models generate insights, including variable selection, scenario assumptions, and uncertainty ranges. This level of clarity not only improves internal decision-making but also facilitates smoother communication during negotiations and health-technology assessments.

Another key recommendation is to promote multidisciplinary collaboration among data scientists, clinicians, health-economists, and regulatory experts to ensure that AI models reflect clinical realities and policy constraints. Health systems and governments should also develop supportive regulatory environments that encourage innovation while safeguarding ethical data use and patient privacy. Training programs that build digital and analytical capacity among market-access teams will further ensure that AI tools are used effectively and responsibly. Collectively, these measures will help unlock the full potential of AI, enabling more equitable access, better pricing alignment, and stronger value demonstration in oncology markets.

REFERENCES

[1]. Abràmoff, M. D., Tobey, D. A., & Shepherd, M. (2022). A reimbursement framework for artificial intelligence in health care. npj Digital Medicine, 5(1), Article 80. https://doi.org/10.1038/s41746-022-00621-w

[2]. Adeoye, J., Akinshipo, A., Koohi-Moghadam, M., Thomson, P., & Su, Y.-X. (2022). Construction of

machine learning-based models for cancer outcomes in low and lower-middle income countries: A scoping review. Frontiers in Oncology, 12, Article 976168. https://doi.org/10.3389/fonc.2022.976168
[3]. Amebleh, J., &Omachi, A. (2022). Data Observability for High-Throughput Payments Pipelines: SLA Design, Anomaly Budgets, and Sequential Probability Ratio Tests for Early Incident Detection. International Journal of Scientific Research in Science, Engineering and Technology, 9(4), 576–591. https://doi.org/10.32628/IJSRSET
[4]. Amebleh, J., Igba, E., &Ijiga, O. M. (2021). Graph-Based Fraud Detection in Open-Loop Gift Cards: Heterogeneous GNNs, Streaming Feature Stores, and Near-Zero-Lag Anomaly Alerts. International Journal of Scientific Research in Science, Engineering and Technology, 8(6). https://doi.org/10.32628/IJSRSET
[5]. Atalor, S. I. (2019). Federated Learning Architectures for Predicting Adverse Drug Events in Oncology Without Compromising Patient Privacy ICONIC RESEARCH AND ENGINEERING JOURNALS JUN 2019 | IRE Journals | Volume 2 Issue 12 | ISSN: 2456-8880
[6]. Atalor, S. I. (2022). Blockchain-Enabled Pharmacovigilance Infrastructure for National Cancer Registries. International Journal of Scientific Research and Modern Technology, 1(1), 50–64. https://doi.org/10.38124/ijsrmt.v1i1.493
[7]. Atalor, S. I. (2022). Data-Driven Cheminformatics Models for Predicting Bioactivity of Natural Compounds in Oncology. International Journal of Scientific Research and Modern Technology, 1(1), 65–76. https://doi.org/10.38124/ijsrmt.v1i1.496
[8]. Anokwuru, E. A., Omachi, A. & Enyejo, L. A. (2022). Human-AI Collaboration in Pharmaceutical Strategy Formulation: Evaluating the Role of Cognitive Augmentation in Commercial Decision Systems *International Journal of Scientific Research in Computer Science, Engineering and Information Technology* Volume 8, Issue 2 Page Number : 661-678 doi : https://doi.org/10.32628/CSEIT2541333
[9]. Barrios, C., de Lima Lopes, G., Yusof, M. M., Rubagumya, F., Rutkowski, P., & Sengar, M. (2022). Barriers in access to oncology drugs — a global crisis. Nature Reviews Clinical Oncology, 20(1), 7–15. https://doi.org/10.1038/s41571-022-00700-7
[10]. Bates, D. W., Landman, A., & Levine, D. M. (2022). Health artificial intelligence: Evidence needed to support AI use in oncology and clinical decision-making. Nature Medicine, 28(1), 34–36. https://doi.org/10.1038/s41591-021-01630-3
[11]. Binder, L. (2022). Health technology assessment process for oncology drugs. Current Oncology, 29(3), 1514-1526. https://doi.org/10.3390/curroncol29030127
[12]. Chandra, V., & Shukla, A. (2022). Artificial intelligence-enabled dynamic pricing for competitive markets: A multi-agent reinforcement learning approach. Journal of Retailing and Consumer Services, 68, 103087. https://doi.org/10.1016/j.jretconser.2022.103087
[13]. Fröling, E., Rajaeean, N., Hinrichsmeyer, K. S., Domrös-Zoungrana, D., Urban, J. N., & Lenz, C. (2022). Artificial intelligence in medical affairs: A new paradigm for identifying and addressing unmet medical needs and care gaps. Pharmaceutical Medicine, 36(1), 1-10. https://doi.org/10.1007/s40290-022-00479-5
[14]. Grace, I., &Okoh, O. F. (2022). Evaluating the impact of online coding platforms on programming skill acquisition in secondary and tertiary education. Acta Electronica Malaysia, 6(1), 16–23. https://doi.org/10.26480/aem.01.2022.16.23
[15]. Gracea, I., &Okohb, O. F.(2022). The Impact Of Artificial Intelligence On Labor Markets And Wage Inequality: A Computational Economic Perspective.
[16]. Ha, S.-Y., Kang, D.-W., Jung, H.-I., Lee, E.-K., & Park, M.-H. (2022). Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies. International Journal of Environmental Research and Public Health, 19(7), 4105. https://doi.org/10.3390/ijerph19074105
[17]. Haleem, A., Javaid, M., & Singh, R. (2022). Artificial intelligence applications for marketing: A review. Journal of Business Research, 149, 150–164. https://doi.org/10.1016/j.jbusres.2022.03.014
[18]. Idika, C. N., Salami, E. O., Ijiga, O. M., &Enyejo, L. A. (2021). Deep Learning Driven Malware Classification for Cloud-Native Microservices in Edge Computing Architectures. International Journal of Scientific Research in Computer Science, Engineering and Information Technology, 7(4). https://doi.org/10.32628/IJSRCSEIT
[19]. Ihimoyan, M. K., Enyejo, J. O. & Ali, E. O. (2022). Monetary Policy and Inflation Dynamics in Nigeria, Evaluating the Role of Interest Rates and Fiscal Coordination for Economic Stability. International Journal of Scientific Research in Science and Technology. Online ISSN: 2395-602X. Volume 9, Issue 6. Doi : https://doi.org/10.32628/IJSRST2215454
[20]. Ijiga, O. M., Ifenatuora, G. P., &Olateju, M. (2021). Bridging STEM and Cross-Cultural Education: Designing Inclusive Pedagogies for Multilingual Classrooms in Sub Saharan Africa. JUL 2021 | IRE Journals | Volume 5 Issue 1 | ISSN: 2456-8880.
[21]. Ijiga, O. M., Ifenatuora, G. P., &Olateju, M. (2021). Digital Storytelling as a Tool for Enhancing STEM Engagement: A Multimedia Approach to Science Communication in K-12 Education. International Journal of Multidisciplinary Research and Growth Evaluation. Volume 2; Issue 5; September-October 2021; Page No. 495-505. https://doi.org/10.54660/.IJMRGE.2021.2.5.495-505
[22]. Ijiga, O. M., Ifenatuora, G. P., &Olateju, M. (2022). AI-Powered E-Learning Platforms for STEM

Education: Evaluating Effectiveness in Low Bandwidth and Remote Learning Environments. International Journal of Scientific Research in Computer Science, Engineering and Information Technology ISSN : 2456-3307 Volume 8, Issue 5 September-October-2022 Page Number : 455-475 doi : https://doi.org/10.32628/IJSRCSEIT199

[23]. Ijiga, O. M., Ifenatuora, G. P., Olateju, M. (2021). Bridging STEM and Cross-Cultural Education: Designing Inclusive Pedagogies for Multilingual Classrooms in Sub Saharan Africa. JUL 2021 | IRE Journals | Volume 5 Issue 1 | ISSN: 2456-8880.

[24]. Ijiga, O. M., Ifenatuora, G. P., Olateju, M. (2021). Digital Storytelling as a Tool for Enhancing STEM Engagement: A Multimedia Approach to Science Communication in K-12 Education. International Journal of Multidisciplinary Research and Growth Evaluation. Volume 2; Issue 5; September-October 2021; Page No. 495-505. https://doi.org/10.54660/.IJMRGE.2021.2.5.495-505

[25]. Ijiga, O. M., Ifenatuora, G. P., Olateju, M. (2022). AI-Powered E-Learning Platforms for STEM Education: Evaluating Effectiveness in Low Bandwidth and Remote Learning Environments. International Journal of Scientific Research in Computer Science, Engineering and Information Technology ISSN : 2456-3307 Volume 8, Issue 5 September-October-2022 Page Number : 455-475 doi : https://doi.org/10.32628/IJSRCSEIT

[26]. Ilesanmi, M. O., Bamigwojo, O. V., Jinadu, S. O, Oyekan, M. & Ijiga, O. M. (2023). Mitigating Regulatory and Market Risks in U.S. Renewable Energy Portfolios : A Portfolio Asset Manager's Perspective *International Journal of Scientific Research in Science and Technology* Volume 10, Issue 6, Pg. 878-906 doi : https://doi.org/10.32628/IJSRST5231103

[27]. James, U. U. (2022). Machine Learning-Driven Anomaly Detection for Supply Chain Integrity in 5G Industrial Automation Systems. International Journal of Scientific Research in Science, Engineering and Technology, 9(2). https://doi.org/10.32628/IJSRSET

[28]. Kline, A., Wang, H., Li, Y., Dennis, S., Hutch, M., Xu, Z., Cheng, F., & Luo, Y. (2022). Multimodal machine learning in precision health. npj Digital Medicine, 5(1), 1-13. https://doi.org/10.1038/s41746-022-00581-7

[29]. Koh, D.-M., Papanikolaou, N., Bick, U., Illing, R., Kahn Jr., C. E., Kalpathi-Cramer, J., Matos, C., Martí-Bonmatí, L., Miles, A., Mun, S. K., … Prior, F. (2022). Artificial intelligence and machine learning in cancer imaging. Communications Medicine, 2, Article 133. https://doi.org/10.1038/s43856-022-00199-0

[30]. Mishra, S., & Krishnaswamy, S. (2022). Artificial intelligence focus and firm performance. Journal of Marketing, 86(6), 82–101. https://doi.org/10.1177/00222429221084346

[31]. Mullin, S., Eissa, M., & Barry, M. (2022). Artificial intelligence applications in oncology market access: Enhancing value-based pricing and reimbursement models. Value in Health, 25(8), 1296–1304. https://doi.org/10.1016/j.jval.2022.05.004

[32]. Nuijten, M. (2022). An integrated valuation model for payer and investor. Journal of Medical Economics, 25(12), 1262-1271. https://doi.org/10.1080/20016689.2022.2080631

[33]. Ocharo, D. O., Onyia, V. O., Bamigwojo, V. O, Adaudu, I. I. & Avevor, J. (2023). Structural and Thermal Behavior of Building-Integrated Photovoltaic (BIPV) Facades in High-Rise Urban Buildings in Philadelphia *International Journal of Scientific Research in Civil Engineering* Volume 7, Issue 5, 161-192 DOI: https://doi.org/10.32628/IJSRCE237418

[34]. Ogayemi, C. (2022). A market access optimization model for new drug launches incorporating artificial intelligence. All Multidisciplinary Journal, 4, 086.

[35]. Okoh, O. F., & Grace, I. (2022). Mathematical modeling and machine learning for economic forecasting: A hybrid approach to predicting market trends. Acta Electronica Malaysia, 6(1), 07–15. https://doi.org/10.26480/aem.01.2022.07.15

[36]. Osamah A. A., Alshehri, Y. A. I., Hamdi, D. H. B., Aminah A. H., Alsultan, S. N., Aldawish, A., … Sharahili, N. A. M. (2022). The use of artificial intelligence in healthcare decision-making. Journal of Population Therapeutics and Clinical Pharmacology, 29(04), 2350-2358. https://doi.org/10.53555/jptcp.v29i04.5367

[37]. Oyekan, M., Jinadu, S. O. & Enyejo, J. O. (2023). Harnessing Data Analytics to Maximize Renewable Energy Asset Performance. International Journal of Scientific Research and Modern Technology, 2(8), 64–80. https://doi.org/10.38124/ijsrmt.v2i8.850

[38]. Parikh, R. B., & Helmchen, L. A. (2022). Paying for artificial intelligence in medicine. npj Digital Medicine, 5(1), Article 63. https://doi.org/10.1038/s41746-022-00609-6

[39]. Poveda, J. L., de Las Heras Rodríguez, R., & Telleria-Aramburu, F. (2022). How can artificial intelligence optimise value-based contracting? Journal of Pharmaceutical Policy and Practice, 15, Article 24. https://doi.org/10.1186/s40545-022-00475-3

[40]. Preston, S., Wei, M., Rao, R., Tinn, R., Usuyama, N., Lucas, M., et al. (2022). Towards structuring real-world data at scale: Deep learning for extracting key oncology information from clinical text with patient-level supervision. arXiv preprint arXiv:2203.10442.

[41]. Rahimi, S. A., Cwintal, M., Huang, Y., Ghadiri, P., Grad, R., Poenaru, D., Gore, G., … Légaré, F. (2022). Application of artificial intelligence in shared decision making: A scoping review. JMIR Medical Informatics, 10(8), e36199. https://doi.org/10.2196/36199

[42]. Rajora, N. (2022). Pharmaceutical drug launch and its readiness in enterprise systems. International

Journal of Advance Research in Computer Science and Management Studies, 10(5), 9–14.
[43]. Ramanathan, R., Subramanian, N., & Yu, W. (2022). Price optimization strategies using machine learning and competitive analytics: Evidence from global markets. Computers & Industrial Engineering, 168, 108037. https://doi.org/10.1016/j.cie.2022.108037
[44]. Regier, D. A., Pollard, S., McPhail, M., Bubela, T., Hanna, T. P., Ho, C., et al. (2022). A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada. npj Precision Oncology, 6(1), Article 1. https://doi.org/10.1038/s41698-022-00316-1
[45]. Simoens, S., De Groote, K., & Boersma, C. (2022). Critical reflections on reimbursement and access of advanced therapies. Frontiers in Pharmacology, 13, Article 771966. https://doi.org/10.3389/fphar.2022.771966
[46]. Tachkov, K., Zemplényi, A., Kamusheva, M., Dimitrova, M., Siirtola, P., Pontén, J., … Kalo, Z. (2022). Barriers to use artificial intelligence methodologies in health technology assessment in Central and East European countries. Frontiers in Public Health, 10, Article 921226. https://doi.org/10.3389/fpubh.2022.921226